Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

LCTX stock hub

Lineage Cell Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LCTXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

341.5M

NYSEAMERICAN

Market data

Live price

Current market quote for this ticker.

Current price

LCTX

In the news

Latest news · LCTX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-105.3

P25 -105.6P50 -46.5P75 -3.1

ROIC-21.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LCTX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

215

Groups with data

Currency

USD

Showing 215 of 215 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000876343
Company name	Lineage Cell Therapeutics, Inc.
Country	United States
Country code	US
Cusip	53566P109
Employees	77
Employees Change	2%
Employees Change Percent	2.67
Enterprise value	$288.2M
Exchange	NYSEAMERICAN
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US53566P1093
Last refreshed	2026-05-10
Market cap	$341.5M
Market cap category	Small-Cap
Price	$1.37
Price currency	USD
Rev Per Employee	189,038.96x
Sector	Healthcare
Sic	2836
Symbol	LCTX
Website	https://www.lineagecell.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-18.6%
EV Sales Forward	9.76x
EV/Sales	19.8x
FCF yield	-5.69%
P/B ratio	7.48x
P/S ratio	23.46x
PS Forward	11.57x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-149.62%
EBITDA Margin	-144.82%
Gross margin	-22.8%
Gross Profit	$-3.3M
Net Income	$-63.5M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-471.61%
Profit Per Employee	$-825,104
ROA	-12.06
Roa5y	-13.52
ROCE	-21.52
ROE	-105.3
Roe5y	-48.6
ROIC	-21.73

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-5.8%
Cagr15y	-8.79%
Cagr1y	208.8%
Cagr20y	9.29%
Cagr3y	-1.42%
Cagr5y	-12.95%
EPS Growth Years	0
Revenue Growth	53.24x
Revenue Growth Q	130.4x
Revenue Growth Quarters	1x
Revenue Growth Years	2x
Revenue Growth3 Y	-0.33x
Revenue Growth5 Y	51.46x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.13
Assets	$112.6M
Cash	$55.8M
Current Assets	$59.2M
Current Liabilities	$11.4M
Debt	$2.4M
Debt Equity	$0.06
Equity	$43.3M
Liabilities	$69.2M
Long Term Assets	$53.4M
Long Term Liabilities	$57.9M
Net Cash	$53.4M
Net Cash By Market Cap	$15.62
Net Cash Growth	17.82%
Net Debt Equity	$-1.23
Tangible Book Value	$2.2M
Tangible Book Value Per Share	$0.01
WACC	12.95

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.2
Net Working Capital	$-7.1M
Quick ratio	5.04
Working Capital	$47.8M
Working Capital Turnover	$0.34

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-14.95%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-44.97%
1Y total return	208.56%
200-day SMA	1.57
3Y total return	-4.2%
50-day SMA	1.59
50-day SMA vs 200-day SMA	50over200
5Y total return	-50%
All Time High	27
All Time High Change	-94.93%
All Time High Date	1997-10-31
All Time Low	0.1
All Time Low Change	1,270%
All Time Low Date	2005-11-07
ATR	0.09
Beta	1.6
Beta1y	0.55
Beta2y	1.14
Ch YTD	-17.96
High	1.4
High52	2.09
High52 Date	2025-11-03
High52ch	-34.45%
Low	1.35
Low52	0.43
Low52 Date	2025-05-08
Low52ch	218.61%
Ma50ch	-13.94%
Premarket Change Percent	0.28
Premarket Price	$1.37
Premarket Volume	6,212
Price vs 200-day SMA	-12.96%
RSI	35.6
RSI Monthly	51.75
RSI Weekly	42.87
Sharpe ratio	1.85x
Sortino ratio	3.47
Total Return	-14.95%
Tr YTD	-17.96
Tr15y	-74.86%
Tr1m	-9.87%
Tr1w	-10.46%
Tr3m	-19.41%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	1
Analyst Price Target Top	$4
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.03
Earnings Revenue Estimate	3,106,800x
Earnings Revenue Estimate Growth	106.84x
Operating Income	$-21.8M
Operating margin	-149.6
Price target	$6.25
Price Target Change	$356
Price Target Change Top	$192

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	187,279,449%
Float Percent	75.12%
Net Borrowing	-59,000
Shares Insiders	5%
Shares Institutions	23.54%
Shares Out	249,298,295
Shares Qo Q	3.63%
Shares Yo Y	14.95%
Short Float	13.51%
Short Ratio	23.25
Short Shares	10.15

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-24.2M
Average Volume	1,257,872.7x
Bv Per Share	0.18
CAPEX	$-522,000
Ch10y	-48.88
Ch15y	-78.43
Ch1m	-9.87
Ch1w	-10.46
Ch1y	208.6
Ch20y	407.4
Ch3m	-19.41
Ch3y	-4.2
Ch5y	-50
Ch6m	-22.16
Change	0%
Change From Open	-0.72
Close	1.37
Days Gap	0.73
Depreciation Amortization	699,000
Dollar Volume	1,598,135.1
Earnings Date	2026-05-12
Earnings Time	amc
EBIT	$-21.8M
EBITDA	$-21.1M
EPS	$-0.28
F Score	4
FCF	$-19.4M
FCF EV Yield	-6.75x
FCF Per Share	$-0.08
Financing CF	26,950,000
Fiscal Year End	December
Founded	1,990
Goodwill	10,672,000
Income Tax	$-5.3M
Investing CF	-13,457,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-05
Last Report Date	2025-12-31
Last Split Date	1997-10-31
Last Split Type	Forward
Last10k Filing Date	2026-03-05
Ma150	1.68
Ma150ch	-18.36%
Ma20	1.54
Ma20ch	-10.98%
Net CF	-5,030,000
Next Earnings Date	2026-05-12
Open	1.38
Optionable	Yes
Position In Range	40
Ppne	4,697,000
Pre Close	1.37
Price Date	2026-05-08
Ptbv Ratio	156.9
Relative Volume	0.93x
Revenue	14,556,000x
SBC By Revenue	32.65x
Share Based Comp	4,752,000
Tax By Revenue	-36.27x
Tr20y	491.3%
Tr6m	-22.16%
Us State	California
Volume	1,166,522
Z Score	-3.73

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LCTX pay a dividend?

Capital-return profile for this ticker.

Performance

LCTX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LCTX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+23.5%

Float: +75.1% of shares outstanding

Insider ownership

+5.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LCTX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

35.6

Neutral momentum band

Price vs 200-day MA

-13.0%

50/200-day relationship not available

Beta (5Y)

1.60

More volatile than the market

Sharpe ratio

1.85

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LCTX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current LCTX stock rating?

Lineage Cell Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full LCTX analysis?

The full report lives at /stocks/LCTX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for LCTX?

The latest report frames LCTX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the LCTX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.